Efficacy of Bifeprunox in Patients With Schizophrenia

• Status: Terminated
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of the study is to evaluate the efficacy of bifeprunox in the maintenance phase of schizophrenia compared to placebo.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: H. Lundbeck A/S
• Treatments: Quetiapine Fumarate

Criteria

Inclusion Criteria:

Main inclusion criteria

• The subject has a primary diagnosis of schizophrenia

• The subject experiences clinically significant symptoms

• The subject's medication remained stable for 8 weeks prior to screening

• The subject is currently in the post-acute maintenance phase of his/her disease

Exclusion Criteria:

Main exclusion criteria

• The subject is at significant risk of suicide

• The subject is treatment resistant

• The subject has experienced an acute exacerbation within 8 weeks prior screening

• The subject is unlikely to comply with the protocol

• The subject has a current diagnosis or a history of substance abuse